CA
IMRX icon

Clearstead Advisors’s Immuneering IMRX Stock Holding History

Clearstead Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Hold
60,865
– – ﹤0.01% 927
2026
Q1 		$321K Buy
+60,865
New +$312K ﹤0.01% 838

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Clearstead Advisors's IMRX Position: Q2 2026 in Review

Clearstead Advisors held its Immuneering (IMRX) position steady in Q2 2026 at 60,865 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Clearstead Advisors first reported a position in IMRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $321K in Q1 2026. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Clearstead Advisors held 60,865 shares of Immuneering worth $304K as of Q2 2026.
  • Clearstead Advisors left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #927 holding.
  • Clearstead Advisors first reported a position in Immuneering in Q1 2026 and has held it in 2 quarters since.
  • Clearstead Advisors's Immuneering position peaked at $321K in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.